News >

Novel Therapies Propelling Progress in Breast Cancer

Jessica Hergert
Published: Wednesday, Sep 11, 2019

Alexander A. Hindenburg, MD, a clinical assistant professor, Department of Medicine, NYU Langone Perlmutter Cancer Center

Alexander A. Hindenburg, MD

The emergence of novel agents, such as CDK4/6 inhibitors and PI3K inhibitors, is shifting the standard of care for patients in metastatic, hormone receptor (HR)–positive, HER2-negative breast cancer, explained Alexander A. Hindenburg, MD. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication